May 14, 2026 8:05am EDT Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026 7:00am EDT Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
